{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"In the Lab with Dr. Rashmi Mishra: Shapeshifting cancer into a more treatable form","description":" John Higgins interviews Dr. Rashmi Mishra, a postdoctoral research fellow in the Hsieh Lab at Fred Hutch Cancer Center, about how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. In a recent study, she and her colleagues found potential ways to reverse that trick, forcing tumor cells to shapeshift back into the more treatable form. Their discovery opens a new line of attack against aggressive prostate cancer, as well as breast cancer and possibly other cancers.  Key Takeaways:  Prostate cancer comprises two main types of cells: luminal, which is more treatable with existing therapies and a more aggressive, lethal type called basal, which is much less treatable.  A recent study by Dr. Rashmi Mishra, a postdoctoral research fellow in the Hsieh Lab at Fred Hutch Cancer Center, describes how prostate cancer shapeshifts from a luminal to a basal form to elude therapy without reprogramming its DNA.  Mishra and her colleagues found potential ways to reverse that shapeshifting trick, forcing tumor cells to shapeshift back into the more treatable form.  Their discovery opens a new line of attack against aggressive prostate cancer, as well as breast cancer and possibly other cancers.  ","author_name":"Bench to Bedside and Beyond","author_url":"https:\/\/sites.libsyn.com\/591875","html":"